MX2023006728A - Esteres de acido dicarboxilico para inducir un efecto analgesico. - Google Patents
Esteres de acido dicarboxilico para inducir un efecto analgesico.Info
- Publication number
- MX2023006728A MX2023006728A MX2023006728A MX2023006728A MX2023006728A MX 2023006728 A MX2023006728 A MX 2023006728A MX 2023006728 A MX2023006728 A MX 2023006728A MX 2023006728 A MX2023006728 A MX 2023006728A MX 2023006728 A MX2023006728 A MX 2023006728A
- Authority
- MX
- Mexico
- Prior art keywords
- inducing
- dicarboxylic acid
- analgesic effect
- acid esters
- methods
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 title 1
- -1 dicarboxylic acid ester Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126387P | 2020-12-16 | 2020-12-16 | |
| PCT/IB2021/061872 WO2022130288A1 (en) | 2020-12-16 | 2021-12-16 | Dicarboxylic acid esters for inducing an analgesic effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006728A true MX2023006728A (es) | 2023-06-19 |
Family
ID=81942874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006728A MX2023006728A (es) | 2020-12-16 | 2021-12-16 | Esteres de acido dicarboxilico para inducir un efecto analgesico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11911358B2 (enExample) |
| EP (1) | EP4262779A4 (enExample) |
| JP (1) | JP7837335B2 (enExample) |
| KR (1) | KR20230131182A (enExample) |
| CN (1) | CN116829141A (enExample) |
| AU (1) | AU2021400215A1 (enExample) |
| CA (1) | CA3202461A1 (enExample) |
| CL (1) | CL2023001737A1 (enExample) |
| CO (1) | CO2023007903A2 (enExample) |
| IL (1) | IL303751A (enExample) |
| MX (1) | MX2023006728A (enExample) |
| WO (1) | WO2022130288A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022022437A2 (pt) | 2020-05-07 | 2023-01-03 | Adorx Therapeutics Ltd | Antagonistas do receptor a2a de adenosina |
| US20260048034A1 (en) | 2024-08-15 | 2026-02-19 | New Frontier Labs, Llc | Compositions and methods for enhancing the efficacy of dicarboxylic acid esters, and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS539788A (en) * | 1976-07-14 | 1978-01-28 | Syntex Inc | 55aloyll1*22dihydroo3hh pyroro *1*22a* pyroll11 carboxylic acid derivative |
| JPH07116026B2 (ja) * | 1987-07-07 | 1995-12-13 | 株式会社資生堂 | ジクロフェナックナトリウム含有乳化外用剤 |
| JP2523428B2 (ja) * | 1992-12-04 | 1996-08-07 | エスエス製薬株式会社 | 消炎鎮痛ゲル製剤 |
| US9265725B2 (en) * | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| JP2004300113A (ja) * | 2003-04-01 | 2004-10-28 | Nichiban Co Ltd | 消炎鎮痛貼付剤 |
| WO2006074379A2 (en) * | 2005-01-07 | 2006-07-13 | Azaya Therapeutics, Inc. | Methods and compositions involving esters of azelaic acid and other dicarboxylic acids |
| US8822509B2 (en) * | 2006-12-29 | 2014-09-02 | The University Of Queensland | Pain-relieving compositions and uses therefor |
| EP2219633A2 (en) * | 2007-11-23 | 2010-08-25 | Nectid, Inc. | Tapentadol compositions |
| US20090326069A1 (en) * | 2008-06-30 | 2009-12-31 | Bltn, Llc | Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers |
| BRPI0901758A2 (pt) * | 2009-05-28 | 2011-01-25 | Cristalia Prod Quimicos Farm | uso de telocinobufagina como analgésico no tratamento das dores aguda e crÈnica; composição farmacêutica contendo telocinobufagina e uso da mesma |
| US20120251525A1 (en) * | 2009-06-30 | 2012-10-04 | Streeper Robert T | Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules |
| EP3445354B8 (en) * | 2016-04-20 | 2022-07-06 | New Frontier Labs, LLC | Azelaic acid esters in the treatment of insulin resistance |
| US20220023423A1 (en) * | 2018-12-19 | 2022-01-27 | Medrx Co., Ltd. | Anti-Inflammatory Analgesic External Preparation |
| CN111544381B (zh) * | 2020-05-12 | 2021-07-16 | 普霖贝利生物医药研发(上海)有限公司 | 一种包含壬二酸的皮肤局部给药组合物 |
-
2021
- 2021-12-16 MX MX2023006728A patent/MX2023006728A/es unknown
- 2021-12-16 IL IL303751A patent/IL303751A/en unknown
- 2021-12-16 KR KR1020237020625A patent/KR20230131182A/ko active Pending
- 2021-12-16 JP JP2023536038A patent/JP7837335B2/ja active Active
- 2021-12-16 AU AU2021400215A patent/AU2021400215A1/en active Pending
- 2021-12-16 CA CA3202461A patent/CA3202461A1/en active Pending
- 2021-12-16 US US17/552,943 patent/US11911358B2/en active Active
- 2021-12-16 EP EP21905954.0A patent/EP4262779A4/en active Pending
- 2021-12-16 WO PCT/IB2021/061872 patent/WO2022130288A1/en not_active Ceased
- 2021-12-16 CN CN202180093764.8A patent/CN116829141A/zh active Pending
-
2023
- 2023-06-14 CL CL2023001737A patent/CL2023001737A1/es unknown
- 2023-06-16 CO CONC2023/0007903A patent/CO2023007903A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021400215A9 (en) | 2025-03-20 |
| CN116829141A (zh) | 2023-09-29 |
| WO2022130288A1 (en) | 2022-06-23 |
| KR20230131182A (ko) | 2023-09-12 |
| EP4262779A4 (en) | 2024-11-13 |
| US11911358B2 (en) | 2024-02-27 |
| CA3202461A1 (en) | 2022-06-23 |
| AU2021400215A1 (en) | 2023-07-06 |
| US20220184023A1 (en) | 2022-06-16 |
| IL303751A (en) | 2023-08-01 |
| CO2023007903A2 (es) | 2023-06-30 |
| CL2023001737A1 (es) | 2024-01-19 |
| JP2023553642A (ja) | 2023-12-25 |
| EP4262779A1 (en) | 2023-10-25 |
| JP7837335B2 (ja) | 2026-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000767A1 (es) | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
| NI202100009A (es) | Métodos para reducir la necesidad de revascu | |
| CY1123749T1 (el) | Μεθοδοι μειωσης του κινδυνου καρδιαγγειακου γεγονοτος σε ενα υποκειμενο επι θεραπειας στατινης χρησιμοποιωντας αιθυλ εστερα εικοσαπενταενοϊκου οξεος | |
| AR084433A1 (es) | Inhibidores de la faah y composiciones farmaceuticas que los contienen | |
| CR11648A (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas | |
| NI201300086A (es) | Composicion de complejo oral que contiene ester de acido graso omega-3 e inhibidor de reductasa hmg-coa | |
| CL2023001737A1 (es) | Ésteres de ácido dicarboxílico para inducir un efecto analgésico | |
| CO6341565A2 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
| AR082444A1 (es) | Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa | |
| AR098899A1 (es) | Composiciones para el cuidado oral y métodos | |
| AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| CL2023001739A1 (es) | Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina | |
| MX390011B (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| ECSP15050273A (es) | Formulación oral para el tratamiento de enfermedades cardiovasculares | |
| UY35445A (es) | Ésteres de testosterona de cadena larga lipoequilibrados para la administración oral | |
| BR112013004714A2 (pt) | "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos" | |
| TW201611830A (en) | Pharmaceutical formulation for reducing bladder spasms and method of use thereof | |
| AR100729A1 (es) | Formulación farmacéutica para reducir la frecuencia de micción y método para su utilización | |
| EA202190859A8 (ru) | Способы снижения риска сердечно-сосудистых событий у субъекта | |
| BR112018075102A2 (pt) | ésteres de ácido graxo de cadeia média de beta-hidroxibutirato e butanodiol e composições e métodos para utilização dos mesmos |